Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-02-17

FDA Approved: AMBRISENTAN — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ambrisentan (Actavis Pharma, Inc.), a drug used to treat pulmonary arterial hypertension. This action expands/re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)